{"filing":{"accession_number":"0001193125-26-239559","cik":"0001831828","ticker":"VERA","company_name":"Vera Therapeutics, Inc.","form":"8-K","filing_date":"2026-05-26","report_date":null,"primary_document":"vera-20260521.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1831828/000119312526239559/vera-20260521.htm"},"events":[{"id":9046,"run_id":7942,"accession_number":"0001193125-26-239559","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder vote results from Vera Therapeutics' 2026 Annual Meeting of Stockholders held on May 21, 2026, covering three proposals: election of Class II directors (Morrisey, Enright, Meyers), ratification of KPMG LLP as independent auditor, and advisory approval of executive compensation. The filing presents final voting tallies for each matter, which is the hallmark of Item 5.07 shareholder_vote_results disclosures.","company_name":"Vera Therapeutics, Inc.","ticker":"VERA","filing_date":"2026-05-26","form":"8-K","submitted_at":null,"items":[{"id":1531,"accession_number":"0001193125-26-239559","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Vera Therapeutics' 2026 Annual Meeting of Stockholders held on May 21, 2026, covering three proposals: election of Class II directors (Morrisey, Enright, Meyers), ratification of KPMG LLP as independent auditor, and advisory approval of executive compensation. The filing presents final voting tallies for each matter, which is the hallmark of Item 5.07 shareholder_vote_results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:12:54.480213+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1531,"accession_number":"0001193125-26-239559","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Vera Therapeutics' 2026 Annual Meeting of Stockholders held on May 21, 2026, covering three proposals: election of Class II directors (Morrisey, Enright, Meyers), ratification of KPMG LLP as independent auditor, and advisory approval of executive compensation. The filing presents final voting tallies for each matter, which is the hallmark of Item 5.07 shareholder_vote_results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:12:54.480213+00:00","company_name":"Vera Therapeutics, Inc.","ticker":"VERA","filing_date":"2026-05-26"}]}